1
|
Didelot JM, Raux B, Didelot R, Rudler F, Mulliez A, Buisson A, Abergel A, Blanc P. What can patients expect in the long term from radiofrequency thermocoagulation of hemorrhoids on bleeding, prolapse, quality of life, and recurrence: "no pain, no gain" or "no pain but a gain"? Ann Coloproctol 2024; 40:481-489. [PMID: 36217810 DOI: 10.3393/ac.2022.00311.0044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Accepted: 06/08/2022] [Indexed: 12/24/2022] Open
Abstract
PURPOSE The purpose of this study was to assess the long-term efficacy of hemorrhoidal radiofrequency thermocoagulation (RFT) on bleeding, prolapse, quality of life (QoL), and recurrence. METHODS This retrospective, single-center study, with RFT performed using procedure modified via hemorrhoid exteriorization assessed the evolution of hemorrhoidal prolapse rated by Goligher scale; bleeding and discomfort (0-10), feeling of improvement and satisfaction (-5 to +5/5) by analog scales; the impact of hemorrhoids on QoL by HEMO-FISS-QoL score. RESULTS From April 2016 to January 2021, 124 patients underwent surgery and 107 were interviewed in September 2021. The average follow-up was 30 months (range, 8-62 months). The mean work stoppage was 3 days, none in 71.0% of the cases. A mean of 4,334 J was applied. No analgesics were required for 66.4% of patients. External hemorrhoidal thrombosis was the only immediate complication in 9 patients, with no long-term reported complication. Bleeding disappeared in 53 out of 102 patients or dropped from 7 to 3 out of 10 (P<0.001). Prolapse reduced from mean grade 3 to 2 (P<0.001), discomfort from 7 to 2 out of 10 (P<0.001). HEMO-FISS-QoL score improved from 22 to 7 out of 100 (P<0.001). Feeling of improvement and overall satisfaction rate were +4/5. Recurrence occurred in 21.5% of patients at 22 months, and 6 required reoperation. Of the patients, 91.6% would choose the same procedure again and 96.3% recommend it. CONCLUSION RFT, although imperfect, leads to a significant improvement in hemorrhoidal symptoms and a lasting increase in QoL with minimal pain and downtime, high acceptance, and low complication and recurrence rates.
Collapse
Affiliation(s)
- Jean-Michel Didelot
- Department of Surgery, Clinique Clémentville, Montpellier, France
- Department of Digestive Medicine B, CHU Saint-Eloi, University of Montpellier, Montpellier, France
| | - Benjamin Raux
- Department of Digestive Medicine, CHU Estaing, University of Clermont-Ferrand, Clermont-Ferrand, France
| | - Romain Didelot
- Department of Digestive Medicine B, CHU Saint-Eloi, University of Montpellier, Montpellier, France
| | - Franz Rudler
- Department of Digestive Medicine B, CHU Saint-Eloi, University of Montpellier, Montpellier, France
| | - Aurelien Mulliez
- Biostatistics Unit, Department of Clinical Research and Innovation, CHRU Clermont-Ferrand, University of Clermont-Ferrand, Clermont-Ferrand, France
| | - Anthony Buisson
- Department of Digestive Medicine, CHU Estaing, University of Clermont-Ferrand, Clermont-Ferrand, France
| | - Armando Abergel
- Department of Digestive Medicine, CHU Estaing, University of Clermont-Ferrand, Clermont-Ferrand, France
| | - Pierre Blanc
- Department of Digestive Medicine B, CHU Saint-Eloi, University of Montpellier, Montpellier, France
| |
Collapse
|
2
|
Laurain A, Bouchard D, Rouillon JM, Petit P, Liddo A, Vinson Bonnet B, Venara A, Didelot JM, Bonnaud G, Senéjoux A, Higuero T, Delasalle P, Tarrerias AL, Devulder F, Castinel A, Thomas C, Pillant Le Moult H, Favreau-Weltzer C, Abramowitz L. French multicentre prospective evaluation of radiofrequency ablation in the management of haemorrhoidal disease. Tech Coloproctol 2023; 27:873-883. [PMID: 37005961 PMCID: PMC10485119 DOI: 10.1007/s10151-023-02787-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Accepted: 03/14/2023] [Indexed: 04/04/2023]
Abstract
PURPOSE The aim of this study was to evaluate the efficacy and safety of radiofrequency ablation (RFA) in the management of haemorrhoidal disease with 1 year's follow-up. METHOD This prospective multicentre study assessed RFA (Rafaelo©) in outpatients with grade II-III haemorrhoids. RFA was performed in the operating room under locoregional or general anaesthesia. Primary endpoint was the evolution of a quality-of-life score adapted to the haemorrhoid pathology (HEMO-FISS-QoL) 3 months after surgery. Secondary endpoints were evolution of symptoms (prolapsus, bleeding, pain, itching, anal discomfort), complications, postoperative pain and medical leave. RESULTS A total of 129 patients (69% men, median age 49 years) were operated on in 16 French centres. Median HEMO-FISS-QoL score dropped significantly from 17.4/100 to 0/100 (p < 0.0001) at 3 months. At 3 months, the rate of patients reporting bleeding (21% vs. 84%, p < 0.001), prolapse (34% vs. 91.3%, p < 0.001) and anal discomfort (0/10 vs. 5/10, p < 0.0001) decreased significantly. Median medical leave was 4 days [1-14]. Postoperative pain was 4/10, 1/10, 0/10 and 0/10 at weeks 1, 2, 3 and 4. Seven patients (5.4%) were reoperated on by haemorrhoidectomy for relapse, and three for complications. Reported complications were haemorrhage (3), dysuria (3), abscess (2), anal fissure (1), external haemorrhoidal thrombosis (10), pain requiring morphine (11). Degree of satisfaction was high (+ 5 at 3 months on a - 5/+ 5 scale). CONCLUSION RFA is associated with an improvement in quality of life and symptoms with a good safety profile. As expected for minimally invasive surgery, postoperative pain is minor with short medical leave. CLINICAL TRIAL REGISTRATION AND DATE Clinical trial NCT04229784 (18/01/2020).
Collapse
Affiliation(s)
- A Laurain
- Clinique Blomet Ramsay santé, 136 rue Blomet, 75015, Paris, France.
- Service de Proctologie, Hôpital Bichat, APHP, 46 Rue Henri Huchard, 75018, Paris, France.
| | - D Bouchard
- Service de Proctologie, Hôpital Bagatelle, 33400, Talence, France
| | - J-M Rouillon
- Service de Gastroentérologie, Polyclinique Montréal, Route de Bram, 11000, Carcassonne, France
| | - P Petit
- Clinique Santé Atlantique, Elsan, 44800, Saint Herblain, France
| | - A Liddo
- Cabinet médical, 1 Quai du Havre, 59200, Tourcoing, France
- Clinique de la Victoire, 1 Quai du Havre, 59200, Tourcoing, France
| | - B Vinson Bonnet
- Service de Chirurgie Digestive CHI Poissy, St Germain, France
| | - A Venara
- Service de Chirurgie Viscérale et Endocrinienne CHU Angers, 4 rue Larrey, Angers, France
| | - J-M Didelot
- Cabinet médical, 1019 Avenue du Pr Louis Ravaz, 34080, Montpellier, France
- Clinique Clémentville, 25 Rue de Clémentville, 34070, Montpellier, France
| | - G Bonnaud
- Clinique Ambroise Paré, 31000, Toulouse, France
| | - A Senéjoux
- Centre Hospitalier Privé, 6 Bd de la Boutière, 35760, Saint Grégoire, France
| | - T Higuero
- Cabinet médical, 11, bd du général Leclerc, 06240, Beausoleil, France
- Clinique Kantys centre, 7 avenue Durante, 06004, Nice, France
| | - P Delasalle
- Clinique du Palais, 25 Avenue Chiris, 06130, Grasse, France
| | | | - F Devulder
- SELARL Hépato-gastroentérologie, 89 rue Louis Victor de Broglie, 51430, Bezannes, France
| | - A Castinel
- Service de Proctologie, Clinique Tivoli Ducos, 91 rue de Rivière, Bordeaux, France
| | - C Thomas
- Service d'Hépato-gastroentérologie, Institut mutualiste Montsouris, 40 boulevard Jourdan, 75014, Paris, France
- Service de Proctologie, Hôpital St Joseph rue Losserand, 75014, Paris, France
| | - H Pillant Le Moult
- Clinique Blomet Ramsay santé, 136 rue Blomet, 75015, Paris, France
- Service de Proctologie, Hôpital St Joseph rue Losserand, 75014, Paris, France
| | | | - L Abramowitz
- Clinique Blomet Ramsay santé, 136 rue Blomet, 75015, Paris, France
- Service de Proctologie, Hôpital Bichat, APHP, 46 Rue Henri Huchard, 75018, Paris, France
| |
Collapse
|
3
|
Christodoulou P, Baloyiannis I, Perivoliotis K, Symeonidis D, Tzovaras G. The role of the Rafaelo procedure in the management of hemorrhoidal disease: a systematic review and meta-analysis. Tech Coloproctol 2023; 27:103-115. [PMID: 36371772 DOI: 10.1007/s10151-022-02730-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/20/2022] [Accepted: 11/08/2022] [Indexed: 11/15/2022]
Abstract
BACKGROUND The aim of this study was to summarize the current evidence regarding the role of the Rafaelo procedure in the management of hemorrhoidal disease (HD). METHODS This study was based on the Cochrane Handbook for Systematic Reviews of Interventions and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A literature search was performed (Medline, Scopus, CENTRAL, and Web of Science) from inception to 25/09/2022. Grey literature databases were also reviewed. The primary endpoint was the pooled complications rate of the Rafaelo procedure in patients with HD. Secondary endpoints included short- (bleeding, pain, thrombosis, necrosis, urinary retention, fever, oedema, anal fissure, and readmission) and long-term (stenosis, meteorism, constipation, anal tags, anal hyposensibility, reoperation, and recurrence) postoperative complication rates. Both prospective and retrospective studies were considered. Quality evaluation was performed via the ROBINS-I tool. Certainty of Evidence was based on the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. RESULTS Overall, 6 non-randomized studies and 327 patients were included. The overall complication rate was 17.6% (95% CI 8.8-26.3%). Short-term complications were bleeding (7.5%, 95% CI 2.5-12.5%), thrombosis (2.2%, 95% CI 0.4-4.8%), and pain (1.6%, 95% CI 0.2-3.3%). Reoperation and recurrence rates were 1.8% (95% CI 0.3-3.4%) and 4.8% (95% CI 1.2-8.4%), respectively. A significant improvement in the presenting symptoms was noted. Method approval and patient satisfaction rates were 89.1% (95% CI 81.7-96.6%) and 95% (95% CI 89.8-100%), correspondingly. Overall CoE was "Very Low". CONCLUSIONS Further randomized controlled trials are required to delineate the exact role of the Rafaelo procedure in HD.
Collapse
Affiliation(s)
| | | | | | | | - George Tzovaras
- Department of Surgery, University Hospital of Larissa, Larissa, Greece
| |
Collapse
|
4
|
Early and midterm results of radiofrequency ablation (Rafaelo ® procedure) for third-degree haemorrhoids: a prospective, two-centre study. Tech Coloproctol 2022; 26:479-487. [PMID: 35305182 PMCID: PMC9072280 DOI: 10.1007/s10151-022-02608-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/08/2021] [Accepted: 02/26/2022] [Indexed: 11/19/2022]
Abstract
Background The aim of this study was to evaluate the safety and efficacy of radiofrequency ablation (RFA) for treating third degree haemorrhoids, with a follow-up over 2 years. Methods We conducted a prospective, two-centre study to assess RFA of third-degree haemorrhoids in an outpatient setting. Treatment was performed under local anaesthesia, optionally in combination with sedation. The primary endpoint was analysis of a proctological symptom score ([PSS] bleeding, itching, pain, soiling) and proctological examination to detect recurrence at 1, 6, 12 and 24 months after surgery. The secondary endpoints were postoperative complications, incidence of postoperative pain, including administration of analgesics and time to return to daily routine. Results Ninety-eight patients were included in the study. The mean age of the patients was 49.1 ± 10.9 (mean ± SD). 83 patients (84.7%) were male and 15 patients (15.3%) were female. The follow-up involved 100% (1 month), 95% (6 months), 86% (12 months) and 74% after 24 months. The individual symptom scores and overall PSS score decreased significantly in comparison to the initial score at each time point assessed. Prolapsed haemorrhoids decreased in comparison to the initial situation (100%) to 7.2% (1 month), 3.5% (6 months), 13.1% (12 months) and 13.7% (after 24 months). Thirteen patients (12.7%) required repeat haemorrhoid therapy during the 2-year follow-up period. The mean maximum pain score after the procedure was 2.5 ± 2.7 (determined with the visual analogue scale), while 33 (33.7%) patients reported having no pain. 59 (60.2%) patients did not take analgesics after the procedure. Eleven patients (11.2%) experienced minor complications (bleeding, fever, cramps, diarrhoea, anal venous thrombosis) but did not require additional treatment. Eight cases (8.2%) of major complications (infection, bleeding, severe pain) required treatment with antibiotics, a second intervention, analgesics or hospitalization. Conclusions RFA is safe and effective for treatment of third-degree haemorrhoids. The main advantages of this new method are its use on an outpatient basis under local anaesthesia, a very low level of postoperative pain and significant control of haemorrhoid symptoms over 2 years.
Collapse
|
5
|
Didelot JM, Didelot R. Radiofrequency thermocoagulation of haemorrhoidal bundles, an alternative technique for the management of internal haemorrhoids. Int J Colorectal Dis 2021; 36:601-604. [PMID: 33111967 DOI: 10.1007/s00384-020-03789-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 10/21/2020] [Indexed: 02/04/2023]
Abstract
PURPOSE To describe our experience of radiofrequency thermocoagulation (RFT), assessing patient symptoms and quality of life (QoL) before and after the intervention. METHODS Between April 2016 and April 2018, 42 outpatients were operated for internal haemorrhoids using RFT. Haemorrhoids were externalised to the anal margin and treated by using the Rafaelo® procedure, using the HPR45i probe (F-Care-Systems) under general anaesthesia. Assessment was performed prior to the intervention and during follow-up for prolapse degree using the Goligher scale; bleeding, improvement, and satisfaction using a verbal analogical scale; and the burden of haemorrhoidal disease using the HEMO-FISS-QoL questionnaire. RESULTS In September 2018, 39 patients (26 males, mean age 51 [22-77]) were interviewed after an RFT intervention, during which a mean of 4.296 J was applied per patient. After a mean follow-up of 15 months, bleeding drastically decreased from 7/10 to 1/10 (p < 0.0001) and entirely stopped in 62% of patients. Prolapse significantly reduced from grade 3 to 2 (p < 0.0001) and completely disappeared in 9 out of 33 patients. Only 49% required postoperative level 2 analgesics, and 7 external thromboses were the only complication reported. Average incapacity for work was 1.72 days. All patients reported improvement of haemorrhoidal disease with a satisfaction rate mean score + 4/5. Haemorrhoidal discomfort decreased from 7/10 to 2/10 (p < 0.0001). HEMO-FISS-QoL score significantly improved, dropping from 24.91 to 5.94 (p < 0.001). Among all patients, 85% would choose RFT again if necessary and 90% would recommend it. CONCLUSION RFT treatment reduced haemorrhoidal bleeding and prolapse, and improved patient QoL.
Collapse
Affiliation(s)
| | - Romain Didelot
- University of Medicine, University of Montpellier, Montpellier, France
| |
Collapse
|